US 12,291,529 B2
Heterocyclic GLP-1 agonists
Wei Huang, Shanghai (CN); Hui Lei, Shanghai (CN); Chunliang Lu, Shanghai (CN); and Haizhen Zhang, Shanghai (CN)
Assigned to Gasherbrum Bio, Inc., South San Francisco, CA (US)
Filed by Gasherbrum Bio, Inc., South San Francisco, CA (US)
Filed on Jul. 2, 2024, as Appl. No. 18/762,532.
Application 18/762,532 is a continuation of application No. 18/628,545, filed on Apr. 5, 2024.
Application 18/628,545 is a continuation of application No. PCT/CN2024/077096, filed on Feb. 9, 2024.
Claims priority of application No. PCT/CN2023/076495 (WO), filed on Feb. 16, 2023; application No. PCT/CN2023/113565 (WO), filed on Aug. 17, 2023; and application No. PCT/CN2023/141034 (WO), filed on Dec. 22, 2023.
Prior Publication US 2024/0376105 A1, Nov. 14, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01)] 28 Claims
 
1. A compound selected from:
 
 
 121
 

OG Complex Work Unit Chemistry
 
 
 142

OG Complex Work Unit Chemistry
  Enantiomer 1
 
 
 143

OG Complex Work Unit Chemistry
  Enantiomer 2
 
 
 144

OG Complex Work Unit Chemistry
  Single unknown enantiomer
 
 
 149

OG Complex Work Unit Chemistry
  Enantiomer 1
 
 
 151

OG Complex Work Unit Chemistry
  Enantiomer 1
 
 
 164

OG Complex Work Unit Chemistry
  Single unknown enantiomer
 
 
 168

OG Complex Work Unit Chemistry
  Enantiomer 1
 
 
 180

OG Complex Work Unit Chemistry
  Single unknown enantiomer
 
 
 181

OG Complex Work Unit Chemistry
  Single unknown enantiomer
 
 
 183
 

OG Complex Work Unit Chemistry
 
 
 195
 

OG Complex Work Unit Chemistry
 
 
 214

OG Complex Work Unit Chemistry
  Enantiomer 1
 
 
 216
 

OG Complex Work Unit Chemistry
 
 
 218
 

OG Complex Work Unit Chemistry
 
 
 221
 

OG Complex Work Unit Chemistry
 
 
 and
 
 
 
 238
 

OG Complex Work Unit Chemistry
 
or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof.